NCT03718299View on ClinicalTrials.gov

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

November 2, 2021

Study Completion Date

November 5, 2021

Conditions

Psoriasis

Interventions

DRUG

Injections of tildrakizumab

given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52

Trial Locations (2)

49418

Site 02, Grandville

92123

Therapeutics Clinical Research, San Diego

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT03718299 - A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis | Biotech Hunter | Biotech Hunter